RENSCHLER MARKUS MD 4
4 · Cyteir Therapeutics, Inc. · Filed Dec 14, 2023
Insider Transaction Report
Form 4
RENSCHLER MARKUS MD
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2023-11-20$1.69/sh+6,304$10,654→ 1,079,677 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-11−2,536→ 2,537 totalExercise: $1.20Exp: 2030-02-24→ Common Stock (2,536 underlying) - Exercise/Conversion
Common Stock
2023-11-20$1.20/sh+2,536$3,043→ 1,082,213 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-11−6,304→ 239,559 totalExercise: $1.69Exp: 2033-02-03→ Common Stock (6,304 underlying)
Footnotes (2)
- [F1]The option vests as to 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
- [F2]The option vests as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.